PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page
 
CMAJ. Apr 15, 2003; 168(8): 985–986.
PMCID: PMC152681
Case report
Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome
Ekrem Algün, Süleyman Alici, Cevat Topal, Serdar Ugras, Reha Erkoç, M. Emin Sakarya, and Nese Özbey
From the Departments of Endocrinology (Algün, Topal), Medical Oncology (Alici), Pathology (Ugras), Nephrology (Erkoç) and Radiology (Sakarya), School of Medicine, Yüzüncü Yil University, Van, Turkey, and the Department of Endocrinology (Özbey), School of Medicine, Istanbul University, Istanbul, Turkey.
Abstract
RENAL CELL CARCINOMA IS CHARACTERIZED by varied manifestations, which include unusual metastatic sites and paraneoplastic and vascular syndromes. We describe the case of a 57-year-old man who presented with high fever, weight loss, palpitations and a tender goitre. We suggest that, in this patient, subacute thyroiditis manifested as a paraneoplastic syndrome of renal cell carcinoma.
A 57-year-old previously healthy man presented with a 1-month history of high fever, weight loss and palpitations. Physical examination revealed a tender goitre with a nodule on either side, one about 3 cm in diameter and the other about 1 cm. Ultrasonography revealed that the thyroid gland had a heterogeneous echogenicity and there were nodules of 36 mm and 14 mm in diameter on the right and left sides, respectively. He had elevated levels of triiodothyronine and thyroxine and a suppressed level of thyrotropin (Table 1). His erythrocyte sedimentation rate was 68 mm/h, and the C-reactive protein level was greater than 206 mg/L. A thyroid scan revealed low radioiodine uptake (less than 1% in 24 hours). A fine-needle aspiration biopsy of thyroid tissue revealed numerous multinucleated histiocytic giant cells and scant epithelioid cells (Fig. 1), as well as degenerated follicular cells and scanty colloid. The cytoplasm of the histiocytic giant cells was syncytial and contained no phagocytosed material. Cytopathologic diagnosis was chronic granulomatous thyroiditis. In addition, the patient had high levels of alkaline phosphatase (1045 [normally < 270] U/L) and gamma-glutamyl transferase (219 [normally 6–49] U/L). A CT scan of the abdomen showed a mass of about 4 х 4 cm on the right kidney.
Table thumbnail
Table 1
figure 24FF1
Fig. 1: Numerous multinucleated histiocytic giant cells and scant epithelioid cells seen in thyroid tissue of man presenting with subacute thyroiditis (May–Grunwald–Giemsa stain; original magnification х 200, reduced by 30%).
A right radical nephrectomy was performed. Pathologic examination revealed grade 2, stage I renal cell carcinoma and coexistent angiomyolipoma. Although the patient received no specific therapy for the thyroiditis, 1 month after the nephrectomy the nodules on the thyroid gland had disappeared, the patient was euthyroid and his erythrocyte sedimentation rate and C-reactive protein, alkaline phosphatase and gamma-glutamyl transferase levels were all normal (Table 1).
Subacute thyroiditis is an acute inflammatory disorder of the thyroid gland most likely due to viral infection.1 No association between subacute thyroiditis and renal cell carcinoma has been reported to date.
Among neoplastic diseases, renal cell carcinoma is recognized for its unpredictable various paraneoplastic syndromes.2,3 The biologic basis for these unusual features of renal cell carcinoma might be the mediation of effects by cytokines, such as interleukin-6 (IL-6), or growth factors produced by the tumour and immune mechanisms.4,5
IL-6 has been shown to be involved in the pathophysiology of paraneoplastic syndromes, in particular the elevation of C-reactive protein and haptoglobin levels but also paraneoplastic cholestasis (Stauffer syndrome), paraneoplastic thrombocytosis, neutrophilia and monocytosis.6 All of these paraneoplastic syndromes spontaneously regress after surgical remove of the neoplastic tissue.
Variations in serum IL-6 levels have also been reported in cases of thyroid dysfunction: increased levels have been found in patients with thyroidal destructive processes such as subacute thyroiditis and some forms of amiodarone-induced thyrotoxicosis, and after percutaneous ethanol injection into “hot” thyroid nodules.7,8,9
In the past, high levels of IL-6 during the course of subacute thyroiditis was thought to be the result of cytokine release from the damaged thyrocyte. However, Yamada and colleagues10 showed that IL-6 levels do not fall along with other parameters of disease activity during treatment with corticosteroids. An alternative explanation may be that elevated IL-6 levels during the course of subacute thyroiditis are the cause, not the result, of the destructive process.
We did not measure the preoperative level of IL-6 in our patient, but his fever, the elevated C-reactive protein level and erythrocyte sedimentation rate, and the paraneoplastic cholestasis were clinical clues of high circulating IL-6 levels. We suggest that the destructive process in the thyroid that presented clinically as subacute thyroiditis may have been triggered by high levels of IL-6.
Resolution of the patient's thyroiditis and its pathologic parameters was much faster than that in the average case of subacute thyroiditis. In addition, the common pathophysiologic influence of IL-6 in thyroiditis and renal cell carcinoma suggests that the subacute thyroiditis manifested as a paraneoplastic syndrome of the renal cell carcinoma.
Footnotes
This article has been peer reviewed.
Contributors: All authors contributed equally to the writing and revising of the article and approved the final version.
Competing interests: None declared.
Correspondence to: Dr. Süleyman Alici, Yüzüncü Yil Üniversitesi Tip Fakültesi, Arastirma Hastanesi Tibbi Onkoloji BD., Van, Turkey 65200; fax 90 432 2155051; suleymanalici/at/yahoo.com
1. Mendelson G. Pathology of thyroid disease. In: Mendelson G, editor. Diagnosis and pathology of endocrine diseases. Philadelphia: JB Lippencott; 1988. p. 37.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med1996; 335:865-75. [PubMed]
3. Lokich JJ, Harrison JH. Renal cell carcinoma: natural history and chemotherapeutic experience. J Urol1975;114:371-4. [PubMed]
4. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: a paradigm of lanthanic disease. Am J Clin Oncol1999;22(3):223-31. [PubMed]
5. Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, deKernion JB, et al. Interleukin-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol Immunother1992;35:97-105. [PubMed]
6. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer1997;72(3):424-30. [PubMed]
7. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E. Serum interleukin 6 in amiodarone induced thyrotoxicosis. J Clin Endocrinol Metab1994;78:423-7. [PubMed]
8. Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A. Interleukin-6: A marker of thyroid-destructive processes? J Clin Endocrinol Metab1994;79:1424-7. [PubMed]
9. Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J Endocrinol Invest 1994;(4):269-74. [PubMed]
10. Yamada T, Sato A, Aizawa T. Dissociation between serum interleukin-6 rise and other parameters of disease activity in subacute thyroiditis during treatment with corticosteroid. J Clin Endocrinol Metab1996;81(2):577-9. [PubMed]
Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of
Canadian Medical Association